glp 1 rosacea glp-1 Facial Restoration After GLP-1 Weight Loss in Sarasota glp-1 rosacea ✨Make your skin

Hansen KS, Mogensen TH, Agergaard J, et al

A., Van Montfrans, G

Rough sheets and smooth tubules

Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained